Program
amrecibart
Its studies are mostly in Venous Thromboembolism · Atrial Fibrillation · Kidney Failure, Chronic · Hemorrhage, led by Regeneron Pharmaceuticals.
Furthest: phase 3, since Feb 18, 20268 company-led studies, 4 open or runningNext primary completion: Feb 9, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 84 open or running | phase 3since Feb 18, 2026 | Oct 19, 2021 | Feb 9, 2027phase 2 · NCT07175428 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05102136 · 56 enrolled · Belgium
- Nov 8, 2022Phase 2 study in Venous ThromboembolismNCT05618808 · 373 enrolled · Belgium, Bulgaria, Canada and more
- Mar 1, 2024Phase 2 study in Venous ThromboembolismNCT06299111 · 195 enrolled · United States, Bulgaria, Canada and more
- May 30, 2024Phase 1 study in HemorrhageNCT06444178 · 224 enrolled · United Kingdom
- Sep 9, 2025Phase 2 study in Atrial FibrillationNCT07175428 · 1,200 planned · United States, Argentina, Brazil and more
- Feb 18, 2026Phase 3 study in Atrial FibrillationPhase 3 reachedNCT07430956 · 2,628 planned · United States, Canada
- Jul 6, 2026Phase 3 study in Venous ThromboembolismNCT07697599 · 1,908 planned · Georgia
- Aug 6, 2026Phase 1 study in Kidney Failure, ChronicNCT07759167 · 36 planned · Belgium
Ahead
- Feb 9, 2027Primary completion: phase 2 study in Atrial FibrillationNCT07175428
- Apr 2, 2027Primary completion: phase 1 study in Kidney Failure, ChronicNCT07759167
- Mar 28, 2029Primary completion: phase 3 study in Atrial FibrillationNCT07430956
- Jun 25, 2029Primary completion: phase 3 study in Venous ThromboembolismNCT07697599
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07759167Kidney Failure, Chronic · Belgium | 1 | Recruiting | Apr 2, 2027 | 36 |
| NCT07697599Venous Thromboembolism · Georgia | 3 | Recruiting | Jun 25, 2029 | 1,908 |
| NCT07430956Atrial Fibrillation · United States, Canada | 3 | Recruiting | Mar 28, 2029 | 2,628 |
| NCT07175428Atrial Fibrillation · United States, Argentina, Brazil and more | 2 | Recruiting | Feb 9, 2027 | 1,200 |
| NCT06444178Hemorrhage · United Kingdom | 1 | Completed | Apr 7, 2025 | 224 |
| NCT06299111Venous Thromboembolism · United States, Bulgaria, Canada and more | 2 | Completed | Mar 27, 2026 | 195 |
| NCT05618808Venous Thromboembolism · Belgium, Bulgaria, Canada and more | 2 | Completed | May 27, 2024 | 373 |
| NCT05102136Healthy Volunteers · Belgium | 1 | Completed | Apr 4, 2023 | 56 |
How it is read
Names in the registry
- “REGN9933”, 8 entries
Conditions, from the studies’ own filings
- Venous Thromboembolism, 3 studies
- Atrial Fibrillation, 2 studies
- Kidney Failure, Chronic, 1 study
- Hemorrhage, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.